Barker, Fingert, Hayes-Jordan and Vadaparampil named to NCAB

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Anna D. Barker
Howard Fingert
Howard Fingert
Andrea Hayes-Jordan
Susan T. Vadaparampil

The White House has named the following individuals to the National Cancer Advisory Board:

  • Anna D. Barker, director of Arizona State University Transformative Healthcare Networks, co-director of the Complex Adaptive Systems Initiative and as a professor of practice within the School of Life Sciences. She is also a former NCI deputy director.

  • Howard Fingert, a long-time biotechnology company executive who now works as an industry consultant. Fingert is a member of the NCI Clinical Trials and Translational Research Advisory Committee and a former industry representative on the FDA Oncologic Drugs Advisory Committee.

  • Andrea Hayes-Jordan, chief of the Division of Pediatric Surgery at the UNC School of Medicine, and surgeon-in-chief at the North Carolina Children’s Hospital.

  • Susan T. Vadaparampil, associate center director of Community Outreach, Engagement, & Equity at Moffitt Cancer Center. She joined the Moffitt faculty after completing postdoctoral training at the NCI. Her work is focused on health disparities.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login